Financial Data and Key Metrics Changes - Total revenues for 2025 were $61.9 million, a 10% increase from $56.1 million in 2024, driven by the successful launch of EMROSI [17] - Gross margins improved to 66.2% in 2025 from 62.8% in 2024, reflecting a favorable product mix and lower inventory costs [17] - The company reported a GAAP net loss of $11.4 million, or $0.47 per share, compared to a loss of $14.7 million, or $0.72 per share in 2024 [18] - Adjusted EBITDA was positive at $2.9 million for 2025, up from $800,000 in 2024, indicating progress towards sustainable profitability [18] Business Line Data and Key Metrics Changes - EMROSI achieved $14.7 million in net sales during the three quarters it was available in 2025, with approximately 53,000 prescriptions written [5][7] - The total prescription volume for EMROSI grew nearly 50% sequentially in Q4 compared to Q3 [8] - The company ended 2025 with approximately 3,500 unique prescribers for EMROSI, surpassing its initial goal of 3,200 [9] Market Data and Key Metrics Changes - Approximately 100 million commercial covered lives have access to EMROSI, with contracts in place with two of the top three group purchasing organizations in the U.S. [10] - The company anticipates contracting with the third major GPO by late Q1 or early Q2 of 2026 [10] Company Strategy and Development Direction - The company aims to improve profitability and expand the commercial footprint of EMROSI while launching one or two additional dermatology products in 2026 [19][25] - Focus on building positive physician and patient experiences with EMROSI to drive prescription demand and improve reimbursement rates [11][12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in continued sales growth and profitability, expecting to remain adjusted EBITDA positive in 2026 [7] - The company anticipates improved reimbursement rates and reduced reliance on co-pay bridging programs as coverage expands [11] - Management highlighted the importance of clinical data and publications in supporting EMROSI's market adoption and reimbursement evaluations [12][14] Other Important Information - The company ended 2025 with a cash position of approximately $24 million, up from $20.3 million at the end of 2024 [18] - Working capital at year-end was $29.4 million, an increase of $16.4 million from the previous year [19] Q&A Session Summary Question: Insights on EMROSI prescriptions trends for Q1 - Management noted that Q1 typically sees a slowdown due to insurance deductible resets and severe weather but expects Q1 prescriptions to surpass Q4 numbers [28][29] Question: Expectations for sequential growth in Q2 - Management indicated that momentum is building and expects Q2 to be stronger than Q1, with a run rate of over 126,000 prescriptions annually [30][46] Question: Clarification on revenue per script and gross-to-net expectations - Management explained that Q4's lower revenue per script was due to reimbursement mix and expects improvements in gross-to-net as reimbursement progresses [32][35][58] Question: Commentary on accounts receivable increase in Q4 - Management confirmed that most of the accounts receivable has been collected and attributed the increase to timing [66] Question: Future gross margins outlook as EMROSI gains coverage - Management expressed optimism for improved margins as EMROSI and other high-margin products become a larger part of the revenue mix [67]

Financial Data and Key Metrics Changes - Total revenue for Q2 2025 was $264.6 million, representing a 9% year-over-year increase [5][27] - Debut net product sales were $96.1 million, up 14% year-over-year, with a gross to net adjustment of 23.3% [27] - NUPLAZID net product sales were $168.5 million, up 7% year-over-year, with a gross to net adjustment of 24.6% [27][28] - R&D expenses increased to $78 million from $76.2 million in the previous year, while SG&A expenses rose to $133.5 million from $117.1 million [28] Business Line Data and Key Metrics Changes - Debut saw a patient base increase to 987 unique patients, up from 954 in Q1 2025 and 920 in Q4 2024, indicating strong growth in new patient starts and persistency [9][10] - NUPLAZID referrals increased by 17% year-over-year, with both referrals and new prescriptions rising sequentially from Q1 to Q2 [15][16] Market Data and Key Metrics Changes - The community setting accounted for approximately three-quarters of new referrals for Debut, indicating successful penetration beyond centers of excellence [41] - The company is expanding its reach in the EU, with named patient supply available in multiple countries [13] Company Strategy and Development Direction - The company is focused on accelerating the commercial trajectory of Debut and sustaining long-term growth for NUPLAZID, while advancing a deep pipeline through rigorous clinical development [31] - The company raised the low end of its NUPLAZID guidance for the year, reflecting confidence in business performance [29] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the continued growth of Debut and NUPLAZID, supported by direct-to-consumer campaigns and field execution [5][15] - The company anticipates sustained growth through the second half of the year and beyond, with several key milestones in the pipeline [16][19] Other Important Information - The company hosted its first R&D Day, showcasing nine programs in development and five Phase II or Phase III data readouts expected through 2027 [7][19] - The company is progressing through the review process with EMA for trofinetide, with a decision expected in 2026 [21] Q&A Session Summary Question: About ACP101's top line approach and key risks - Management indicated that the focus will be on the primary endpoint and key safety and tolerability overview in the top line announcement, with ongoing monitoring of assessment variability [33][34] Question: Momentum in Debut and community setting penetration - Management reported that approximately three-quarters of new referrals came from non-center of excellence accounts, indicating successful penetration [41] Question: Discontinuations for Debut and inventory changes - Discontinuations remained below 10%, reflecting a stable patient base, and there were no significant inventory changes reported [73][74] Question: Growth perspective for 2026 - Management expects continued growth for both Debut and NUPLAZID, driven by new field force models and ongoing campaigns [96][100]

Financial Data and Key Metrics Changes - Total revenue increased by 20% in the second quarter, reaching $63.2 million, with gross margin expanding over 400 basis points to 74% [5][12][16] - Adjusted EBITDA rose by 112% year-over-year to over $13.4 million, representing 21% of revenue, an increase of more than 900 basis points compared to the previous year [5][17] - Net loss narrowed to $600,000 or $0.01 per share, an improvement of over $4 million compared to the prior year [17] Business Line Data and Key Metrics Changes - MACI generated record revenue of nearly $54 million, reflecting a 21% increase year-over-year and 15% sequential growth [5][12] - Epicel revenue was $8.6 million, representing an 11% growth year-over-year, with biopsies increasing nearly 40% [14][15] - NexoBrid revenue reached $1.2 million, showing a 52% growth compared to the prior year [15] Market Data and Key Metrics Changes - MACI biopsy growth rates outpaced implant growth, with expectations for convergence in the second half of the year [6][7] - The treatment of small femoral condyle defects increased by 40% year-over-year, indicating strong market potential [7][8] - Epicel's performance rebounded with the highest monthly biopsies recorded in June [9][10] Company Strategy and Development Direction - The company plans to expand its MACI sales force from 76 to approximately 100 territories to support anticipated growth [8][10] - FDA clearance for the Phase III MACI Ankle clinical study was received, representing a significant long-term growth opportunity [10][11] - The company is focused on maintaining strong revenue and profitability growth while preparing for international expansion, particularly in Europe [85] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strong underlying business fundamentals and growth drivers for MACI and burn care products [5][20] - The company is optimistic about the third quarter, citing strong momentum from both MACI and burn care products [10][20] - Management acknowledged challenges in predicting Epicel revenue due to patient health-related issues but remains hopeful for improved performance [39][40] Other Important Information - The company ended the second quarter with approximately $164 million in cash and investments and no debt [17] - The company is not assuming additional NexoBrid revenue related to the BARDA RFP process but sees potential for incremental revenue in the fourth quarter [18][19] Q&A Session Summary Question: What impacted MACI growth in Q2? - Management noted that Q2 revenue was slightly below expectations due to timing issues with some implants moving into July, but overall metrics remain strong [24][25] Question: How many arthrobiopsies have converted to MACI? - Management did not disclose specific conversion rates but indicated that trends are in line with expectations [28][29] Question: What is the new reality for Epicel guidance? - Management explained that while biopsies were up significantly, patient health issues have affected revenue, leading to a more conservative guidance for the second half of the year [32][34] Question: Can you discuss the BARDA RFP? - Management confirmed that the RFP is in the public domain, with proposals due in late August, and initial procurement would be for 2,750 units [92][93]

Group 1 - The core viewpoint of the news is that Hillstone Technology (丘钛科技) is expected to report a significant increase in mid-term net profit, with projections indicating a year-on-year rise of 1.5 to 1.8 times, reaching a median of 305 million RMB, which is 20% higher than market expectations [1] - Standard Chartered Bank reported that Hillstone Technology's stock was deposited with them, with a market value of 3.162 billion HKD, accounting for 25.22% [1] - Citigroup also noted that the market is likely to respond positively to Hillstone Technology's earnings forecast, which is expected to be between 288 million to 323 million RMB, with a median of 305 million RMB, aligning with their annual expectations [1] Group 2 - Hillstone Technology disclosed sales data for its main products, reporting a total of 34.348 million camera modules sold, which is a 1.3% increase quarter-on-quarter and a 4.1% increase year-on-year [2] - The sales of mobile camera modules reached 32.648 million units, reflecting a 0.8% increase quarter-on-quarter and a 1.5% increase year-on-year [2] - The sales of fingerprint recognition modules totaled 13 million units, showing a year-on-year growth of 7.3% [2]

Group 1: Financial Performance - The company's net profit for 2024 is expected to grow significantly, driven by increased sales of key products, particularly the exclusive traditional Chinese medicine An Nao Wan/Pian, which achieved sales of CNY 182 million, an increase of CNY 81.7 million, representing over 80% year-on-year growth [1] - Sales expenses decreased by 25.82%, management expenses (excluding stock incentive costs) decreased by 18.29%, and financial expenses decreased by 103.41% due to the repayment of all bank loans [2] - The company's operating revenue for 2024 was CNY 2.441 billion, a year-on-year decline of 7.06%, primarily due to the impact of centralized procurement [5] Group 2: Product Growth Expectations - An Nao Wan/Pian is expected to have significant growth potential due to its strong qualifications and untapped market in hospitals, especially tier-three hospitals [3] - The injection of multiple vitamins (12) is anticipated to maintain steady growth, with the company holding over 80% market share [3] - The company expects stable growth for the deer melon peptide injection in 2025 and anticipates significant growth for the new product, Siglitin Metformin Sustained Release Tablets, after its launch in July 2024 [3][4] Group 3: Cost Management and Efficiency - The company aims to continue reducing costs, with sales expenses down 27.63%, financial expenses down 82.43%, and management expenses down 20.97% in Q1 2025 [4] - The company plans to maintain low levels of expenses through improved internal management [4] Group 4: Investment and Shareholder Returns - The company has implemented a share repurchase plan, utilizing approximately CNY 80 million to buy back 32.3 million shares, representing 1.42% of the total share capital prior to the buyback [9] - Future measures to enhance investor returns include focusing on core business, disposing of inefficient assets, and exploring new product opportunities [10] Group 5: Research and Development - The company plans to invest approximately CNY 97 million in R&D for 2024, focusing on generic drugs, with no current investment in innovative drugs [4]